



Quality



Trustworthiness



Commitment



Hardwork



# Aptus Pharma Limited

Connecting.....Life

Since  
2011

www.aplus-pharma.com | info@apluspharma.com | export@apluspharma.com | +91 76004 27827

To,  
The Deputy Manager  
Corporate Relationship Department  
**BSE Limited**  
P. J. Towers, Dalal Street,  
Mumbai – 400001

**Scrip Code:** 544529

**ISIN:** INE15XJ01010

**Subject: Outcome of the Board Meeting held on November 10, 2025.**

**Dear Sir/Madam,**

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e., Monday, November 10, 2025, inter alia, considered and approved the following:

The Unaudited Financial Results of the Company for the half year ended September 30, 2025, along with the Limited Review Report issued by the Statutory Auditors, have been approved by the Board of Directors. The copy of the same is enclosed herewith as Annexure.

Further, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of conduct for Prohibition of Insider Trading, the "Trading Window" for trading in the shares of the Company will open from 13<sup>th</sup> November, 2025. for the Designated Persons and their immediate relatives.

The meeting of the Board of Directors commenced at 04:00 PM (IST) and concluded at 06:30 pm PM (IST)

You are requested to kindly take the same on record and disseminate the information on your website.

Thanking you,

Yours faithfully,

**For Aptus Pharma Limited**

**Tejash Maheshchandra Hathi**  
**Managing Director**  
**DIN: 03151221**



# APTUS PHARMA LIMITED

(Formerly Known as Aptus Pharma Private Limited)

CIN:U24230GJ2010PLC61957

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR HALD YEAR ENDED ON 30TH SEPTEMBER 2025

PARTICULARS	(Rs. In Lacs)		
	As at 30/09/2025 (Unaudited)	As at 30/09/2024 (Unaudited)	As at 31/03/2025 (Audited)
<b>INCOME</b>			
I. Revenue From Operation	1,437.75	975.57	2,455.77
II. Other Income	1.22	0.32	7.87
<b>III. Total Income(I+II)</b>	<b>1,438.97</b>	<b>975.88</b>	<b>2,463.64</b>
<b>IV. Expenses:</b>			
(a) Cost of Material Consumed	-	-	-
(b) Purchase Of Stock - in - Trade	911.43	579.89	1,266.93
(c) changes in Inventories	(329.35)	(210.15)	(363.24)
(d) Employee Benefit Cost	230.43	153.91	367.13
(e) Finance Cost	45.30	10.84	46.62
(f) Depreciation And Amortization Cost	16.12	11.19	26.34
(g) Other Expense	329.93	254.66	710.22
<b>Total Expenses [ (a) to (f) ]</b>	<b>1,203.85</b>	<b>800.34</b>	<b>2,053.98</b>
V. Profit Before Exceptional And Extraordinary Items and tax (III-IV)	235.11	175.55	409.66
VI. Exceptional Items			
VII. Profit Before Extraordinary Items and Tax (V-VI)	235.11	175.55	409.66
VIII. Extraordinary Items			
<b>IX. Profit Before Tax (VII-VIII)</b>	<b>235.11</b>	<b>175.55</b>	<b>409.66</b>
<b>IX. Tax Expense</b>			
(1) Current Expense	60.00	45.00	113.45
(2) Deferred Tax	(0.99)	-	(1.90)
(3) Prior Period Taxation Adjustments	1.42	-	2.28
X. Profit (Loss) For the period From Continuing Operations (VIII-IX)	174.69	130.55	295.83
XI. Profit/(Loss) For the period from Discontinuing Operations			
XII. Tax Expense Of Discontinuing Operations			
XIII. Profit/(loss) From Discontinuing Operations(XII-XIII)			
<b>XV. Profit(loss) For the period(XI-XIV)</b>	<b>174.69</b>	<b>130.55</b>	<b>295.83</b>
XIV. Earning Per Share :			
(1) Basic (EPS Not annulised for Half Year ended)	3.46	17.92	6.08
(2) Diluted (EPS Not annulised for Half Year ended)	3.46	17.92	6.08

For and on behalf of  
Aptus Pharma Limited

Place : Rajkot  
Date : 10th November, 2025

Managing Director  
Tejash Hathi  
DIN : 03151221





**APTUS PHARMA LIMITED**

(Formerly Known as Aptus Pharma Private Limited)

CIN: U24230GJ2010PLC061957

**STATEMENT OF UNAUDITED ASSETS AND LIABILITIES AS AT ON 30TH SEPTEMBER 2025**

(Rs. In Lacs)

PARTICULAR	As at 30/09/2025 (Unaudited)	As at 31/03/2025 (Audited)
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Fund</b>		
(a) Share Capital	686.00	500.00
(b) Reserves & Surplus	1,484.19	193.50
(c) Share Application Money	-	-
<b>Total Shareholder's Fund</b>	<b>2,170.19</b>	<b>693.50</b>
<b>(2) Share Money Pending Allotment</b>		
<b>(3) Non-current Liabilities</b>		
(a) Long term borrowings	213.35	262.04
(b) Deferred tax liabilities	-	-
(c) Other Long term liabilities	-	-
(d) Long Term Provisions	24.98	24.98
<b>Total of Non-Current Liabilities</b>	<b>238.33</b>	<b>287.02</b>
<b>(4) Current Liabilities</b>		
(a) Short Term Borrowings	600.18	773.64
(b) Trade Payables		
(i) Total outstanding dues to micro and small enterprise	508.26	75.59
(ii) Total outstanding dues to other creditors	84.64	55.29
(c) Other Current Liabilities	136.75	186.72
(d) Short Term Provisions	220.38	118.83
<b>Total of current Liabilities</b>	<b>1,550.21</b>	<b>1,210.07</b>
<b>Total [(1) + (2) + (3) + (4)]</b>	<b>3,958.73</b>	<b>2,190.60</b>
<b>II. ASSETS</b>		
<b>(1) Non Current Assets</b>		
(a) Property Plant and equipments & Intangible Assets		
(i) Property Plant And Equipments	114.39	96.31
(ii) Intangible Asset	3.94	1.26
(iii) Capital Work in Progress	-	-
(iv) Intangible asset Under development	-	-
(b) Non current Investments	-	-
(c) Deferred Tax Asset(net)	8.45	7.46
(d) Long Term Loans And Advances	-	-
(e) Other Non-current Assets	113.05	111.96
<b>Total of Non-Current Assets</b>	<b>239.84</b>	<b>216.99</b>
<b>(2) Current assets</b>		
(a) Current Investments		
(b) Inventories	1,035.15	705.80
(c) Trade Receivables	1,007.01	563.94
(d) Cash and Cash Equivalents	1,428.16	521.43
(e) Short term loans and advances	248.56	182.44
(f) Other Current Assets		
<b>Total of Current Assets</b>	<b>3,718.88</b>	<b>1,973.61</b>
<b>Total[(1) + (2)]</b>	<b>3,958.73</b>	<b>2,190.60</b>

For and on behalf of  
Aptus Pharma LimitedManaging Director  
Tejash Hathi  
DIN : 03151221

Place : Rajkot

Date : 10th November, 2025

**APTUS PHARMA LIMITED**  
(Formerly Known as Aptus Pharma Private Limited)  
CIN: U24230GJ2010PLC061957

**CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2025**

(Rs. In Lacs)

PARTICULARS	FOR THE YEAR/PERIOD ENDED	
	As at 30/09/2025 (Unaudited)	As at 31/03/2025 (Audited)
<b>I CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Surplus/ (Deficit) before tax	235.11	409.66
Add:		
Depreciation	16.12	26.34
Gratuity	-	(7.76)
Exchange Rate Difference	-	-
Profit/Loss on Sale of Assets	-	-
Write off/Reserves & Surplus Adjustment	-	-
Interest Paid	45.30	46.62
	<b>296.53</b>	<b>474.85</b>
Less: Interest Income	1.22	7.71
<b>Operating cash before working capital changes</b>	<b>295.32</b>	<b>467.15</b>
(Increase)/ Decrease in operating assets :		
Inventories	(329.35)	(363.24)
Trade Receivables	(443.07)	(228.56)
Short Term Loan and Advances	(66.12)	(119.62)
Long Term Provisions	-	24.98
Other Current Asset	-	-
Other Non-Current Asset	(1.10)	(10.43)
	<b>(839.63)</b>	<b>(696.87)</b>
Increase/ (Decrease) in operating liabilities :		
Trade Payables	462.01	(4.53)
Other Current Liabilities	(49.96)	79.72
Short Term Provisions	101.55	86.45
	<b>513.59</b>	<b>161.63</b>
<b>Cash generated from operations</b>	<b>(30.72)</b>	<b>(68.09)</b>
Less: Tax paid	61.42	115.73
<b>Net cash flow from operating activities (I)</b>	<b>(92.14)</b>	<b>(183.82)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Interest Income	1.22	7.71
Purchase of Fixed Assets	36.90	(62.16)
Subsidy Received	-	-
Sale of Fixed Assets	-	-
Increase in Non Current Investment	-	-
<b>Net cash flow from Investing activities (II)</b>	<b>(35.68)</b>	<b>(54.46)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Increase / (Decrease) in Share Capital	186.00	70.00
Increase / (Decrease) in Capital Reserves	1,116.00	140.00
Increase / (Decrease) in Long Term Borrowings	(48.69)	(133.91)
Increase / (Decrease) in Other Long Term Liabilities	-	-
Increase / (Decrease) in Short Term Borrowings	(173.46)	638.78
Interest Paid	(45.30)	(46.62)
<b>Net cash Flow from Financing activities (III)</b>	<b>1,034.56</b>	<b>668.25</b>
<b>Net increase/(decrease) in cash and cash equivalents: (I+II+III)</b>	<b>906.74</b>	<b>429.98</b>
<b>Opening Cash/cash equivalents</b>	<b>521.43</b>	<b>91.45</b>
<b>Closing Cash/cash equivalents</b>	<b>1,428.16</b>	<b>521.43</b>

Notes:

1. The above Cash flow statement has been prepared under the indirect method set out in accounting standard-3, "Cash Flow statement" notified under section of the Companies Act 2013, read together with paragraph 7 of the companies (Accountants) Rules 2014.

For and on behalf of  
Aptus Pharma Limited

Managing Director  
Tejash Hathi  
DIN : 03151221

Place: Rajkot  
Date : 10th November, 2025





Notes to Financial Results

1. The above Financial results were reviewed by the audit committee and then approved by the board of directors in their meeting held on 10<sup>th</sup> November, 2025.
2. These financial results prepared in accordance with the recognition and measurement principles of accounting standards (AS) prescribed under section 133 of the companies act, 2013 read with the relevant rules issued thereunder and other accounting Principles generally accepted in India.
3. The Earning Per Share (EPS) have been Computed in accordance with Accounting standard on Earning Per share (EPS) AS-20. The EPS for the half year ended 30<sup>th</sup> September 2025 & 2024 is not annualized, working of the same is as under;

Particulars	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)	31-03-2025 (Audited)
A. Profit/Loss attributable to equity Shareholders	174.69	130.55	295.83
B. Weighted average No. Of shares	50,50,820	7,28,415	48,63,836
C. Nominal Value of equity shares	10.00	10.00	10.00
D. Basic EPS (Rs.) (A)/(B)	3.46	17.92	6.08
E. Diluted EPS (A)/(B)	3.46	17.92	6.08

4. The company is primarily engaged in the business of marketing, and distribution of finished pharmaceutical formulations, which in the context of Accounting Standard 17 on segment Reporting on "Segment Reporting" not applicable.
5. The details of utilization of IPO Proceeds of Rs. 1302.00 lakhs are as follows:

Rs. Lacs			
Particulars	Proceeds	Utilization up to September 30th, 2025	Unutilized up to September 30th, 2025
Capital Expenditure for office Premises with furniture and industrial Racks	162.95	0	162.95
Working Capital	800.00	0	800.00
General Corporate Purpose	191.05	0	191.05
Issue Related Expense	148.00	0	148.00
Total	1302.00	0	1302.00


*[Handwritten signature]*  
H 7 th 11 th



6. The previous year/periods figures have been regrouped/reclassified wherever necessary to correspond with the current period classification for the comparison.

For and on the behalf of  
**Aptus Pharma Limited**  
CIN: U24230GJ2010PLC061957

Place : Rajkot  
Date : 10/11/2025

  
Tejash Hathi  
Managing Director  
DIN: 03151221



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS OF THE APTUS PHARMA LIMITED FOR THE PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED**

To,  
The Board of Directors  
Aptus Pharma Limited  
(Formerly Known as Aptus Pharma Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Aptus Pharma Limited** ("the Company") for the half year ended 30<sup>th</sup> September, 2025, attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation").
2. The preparation of statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, in accordance with the recognition and measurement principles laid down in Accounting Standards 25, (AS 25) "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation"). Our responsibility is to issue a report on these financial results based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





---

**A B K B & Co.**  
**Chartered Accountants**

---

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the applicable accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot

Date: 10<sup>th</sup> November, 2025



FOR, A B K B & Co.  
Chartered Accountant  
FRN: 136695W

(CA Maulik S. Bagdai)  
Partner

MEM. NO. 135216  
UDIN: 25135216 BMLXKA7421



## Aptus Pharma Limited Reports 47% YoY Revenue Growth, PAT surges 33% in H1 FY26

- H1FY26 Total Revenue of Rs. 1437.75 Lakhs; Up 47.38% YoY
  - H1FY26 EBITDA of Rs. 294.55 Lakhs; Up 36.12% YoY
    - H1FY26 PAT at Rs. 174.59 Lacks; Up 33.81%

**Rajkot:** Aptus Pharma Limited (BSE:), a fast-growing pharmaceutical company focused on the sales and marketing of high-quality medicines, has announced a strong set of financial results for the first half of FY26 ended on September 30, 2025 demonstrating solid growth momentum and operational excellence.

### Key Standalone Financial Highlights (Rs. In Lakhs)

Particulars	Standalone Financials		
	H1FY26	H1FY25	YoY%
Total Revenue	1,437.75	975.57	47.38%
EBIDTA	294.55	216.39	36.12%
EBIDTA Margin	20.49%	22.18%	-169 bps
PAT	174.69	130.55	33.81%
PAT Margin	12.15%	13.38%	-123 bps

### Performance Overview:

We are pleased to announce that APL has delivered a strong performance for the first half of FY26, continuing its growth momentum across key financial and operational parameters. During **H1 FY26**, our **Revenue grew by 47.38%**, **EBITDA increased by 36.12%**, and **Profit After Tax (PAT)** recorded a growth of **33.81%** compared to the corresponding period of the previous year. This performance reflects the success of our strategic initiatives in expanding our product portfolio, strengthening our marketing network, and driving higher operational efficiency. Despite a competitive environment, we achieved healthy growth in both acute and chronic therapy segments, supported by new product launches and enhanced field force productivity.

Our focus on disciplined cost management and efficient resource utilisation contributed to improved EBITDA margins. The strong PAT growth demonstrates the underlying strength of our business model and our ability to deliver sustainable profitability. we continue to prioritise quality, compliance, and ethical marketing practices. Our teams remain committed to ensuring greater accessibility of affordable and effective medicines to patients across India.

h1 h1 th




Looking ahead, we are confident of maintaining our growth trajectory in the second half of FY26. The Company will continue to invest in new product introductions, digital engagement initiatives, and the expansion of our distribution reach to drive long-term value for all stakeholders.

**Commenting on Our Results, Mr. Tejash Hathi, Managing Director, Aptus Pharma Limited:**

“Our strong performance in the first half of FY26 is a reflection of the collective effort, passion, and dedication of our employees across every function of the organisation. We firmly believe that our people are the biggest reason behind our success. Their commitment to excellence, agility in execution, and unwavering focus on serving patients have been the driving forces of APL’s growth story.

As we continue to expand our presence and strengthen our portfolio, we remain deeply grateful to our team for consistently turning challenges into opportunities. Together, we are building a stronger, more innovative, and growth-centric organisation that is well-positioned for sustained growth in the years ahead.”

Thank you.

  
Tejash Hathi







**Aptus Pharma Limited**

Connecting.....Life

Since  
2011

## Half-Year Unaudited-2025-26 Financial Highlights

Aptus Pharma Limited for the half-year has reported its financial results for the half-year of the Financial year 2025-26, which ended on September 30, 2025.

Key highlights from the financial results as belows

(₹ In Lacs)

Revenue

YoY Growth

₹ 1437.75

47.38 %

Net Profit

₹ 174.69

12.15 %

EBITDA

YoY Growth

₹ 294.55

36.12 %

EBITDA

₹ 294.55

20.49 %

  
**Aptus Pharma**  
(Pioneer Division)

**APTUS WellCare**  
(Health And Personal Care Division)

  
**APTUS CD CARE**  
(Cardiac Diabetic Division)

**APTUS Global**  
(Export Division)

[www.apтус-pharma.com](http://www.apтус-pharma.com)

